27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Allergan plc Ordinary Shares (NYSE: AGN), Alcon, Shire PLC (ADR) (NASDAQ: SHPG) and, to a lesser extent, Bausch & Lomb are the active buyers of ophthalmology products/companies, according to a note from Bernstein citing venture capitalist Emmett Cunningham.
Of note, Alcon is a subsidiary of Novartis AG (ADR) (NYSE: NVS) and Bausch & Lomb was acquired by Valeant Pharmaceuticals Intl Inc (NYSE: VRX).
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Cunningham is an ophthalmologist, a partner at Clarus Funds and a leading venture capitalist in the eye-care space.
"We wonder if Shire is not highly motivated to buy one of the two Glaucoma companies – Aerie or Inotek," analyst Aaron "Ronny" Gal posed.
In addition to the top active buyers, Gal looked further into the sector.
The note said, Genentech is active in ophthalmology but are only looking for large improvement over standard of care (first-in-class/best-in class)," while Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is somewhat active in the space as well.
Bernstein rates Allergan at Outperform, with a price target of $335. Shire is also rated Outperform, with a price target of $222.
At the time of writing, shares of Allergan were down 1.26 percent to $246.81, and Regeneron Pharma dropped 0.65 percent to $386.44. Meanwhile, ADRs of Shire also fell 1.45 percent to $185.88.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.